Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;93(1):46-47.
doi: 10.1002/jmv.26110. Epub 2020 Aug 13.

Feasibility of tocilizumab in ICU patients with COVID-19

Nahéma Issa  1 , Margot Dumery  1 , Olivier Guisset  1 , Gaelle Mourissoux  1 , Fabrice Bonnet  2 , Fabrice Camou  1
Affiliations
Comment

Feasibility of tocilizumab in ICU patients with COVID-19

Nahéma Issa et al. J Med Virol. 2021 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Mehta P, McAuley DF, Brown M, et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033‐1034. - PMC - PubMed
    1. Moore JB, June CH. Cytokine release syndrome in severe COVID‐19. Science. 2020;368(6490):473‐474. - PubMed
    1. Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020:1–8. 10.1002/jmv.25964 - DOI - PMC - PubMed
    1. Antwi‐Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID‐19 patients treated with Tocilizumab: an individual patient data systematic review. J Med Virol. 2020:1–7. 10.1002/jmv.26038 - DOI - PMC - PubMed
    1. Di Giambenedetto S, Ciccullo A, Borghetti A, et al. Off‐label use of Tocilizumab in patients with SARS‐CoV‐2 infection [online ahed of print]. J Med Virol. 2020. 10.1002/jmv.25897 - DOI - PMC - PubMed

Substances